Michael J. Birrer Institution Verified

Sourced from institutional research profiles (UAMS TRI or ARA).

High Impact

Director

University of Arkansas for Medical Sciences

faculty

23 h-index 56 pubs 10,573 cited

Research Areas

Cancer Treatment and Pharmacology Cancer Genomics and Diagnostics Cancer-related molecular mechanisms research Immune Response and Inflammation Bioinformatics and Genomic Networks Metabolomics and Mass Spectrometry Studies Cancer Immunotherapy and Biomarkers Health and Medical Research Impacts

Links

ORCID Lab Website Research Group UAMS TRI Profile

Edit your profile

OverviewAI-generated summary

Michael J. Birrer's research focuses on understanding and improving treatments for ovarian cancer, with recent work investigating multiomic analyses to identify therapeutic targets like CPT1A in platinum-refractory, high-grade serous ovarian cancer. He also studies the influence of mechanical forces on ovarian cancer progression and explores genetic variants impacting PARP inhibitor sensitivity.

His work extends to evaluating the safety and efficacy of novel therapeutic agents, such as mirvetuximab soravtansine for folate receptor alpha–expressing recurrent ovarian cancer and PRGN-2009 immunotherapy in combination with pembrolizumab for recurrent or metastatic cervical cancer. Birrer also employs computational approaches, including DAGBagM, to identify protein biomarkers for treatment response in ovarian cancer.

With an h-index of 23 and over 10,000 citations, Birrer is recognized as a highly cited researcher. He leads a research group at the University of Arkansas for Medical Sciences and collaborates with other researchers within the institution, including Rangaswamy Govindarajan.

Metrics

h-index: 23
Publications: 56
Citations: 10,573

Selected Publications

Quality-of-life outcomes in newly diagnosed advanced cancer: subgroup analysis – a case for individual differences (2026) DOI
Abstract A044: Application of HRDefine: a biomarker for identifying root causes of homologous recombination deficiency to a phase 3, randomized, placebo-controlled trial of veliparib in front-line treatment of advanced ovarian cancer (VELIA/GOG-3005) (2025) DOI
miRNA(s) expression as predictive biomarkers in recurrent/metastatic cervical cancer: The NRG Oncology/GOG-0240 NIH Cancer Moonshot. (2025) DOI
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha–expressing recurrent ovarian cancer: An integrated safety summary (2024) DOI
A spatial proteomic study of platinum-refractory, high-grade serous ovarian cancer implicates dual AKT and WNT activity linked to an immunosuppressive tumor microenvironment (2024) DOI
A phase 2 study to evaluate efficacy and safety of PRGN-2009, a novel gorilla adenovirus-based immunotherapy, in combination with pembrolizumab versus pembrolizumab monotherapy in patients with recurrent or metastatic cervical cancer. (2024) DOI
DAGBagM: learning directed acyclic graphs of mixed variables with an application to identify protein biomarkers for treatment response in ovarian cancer (2022) DOI
Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer (2021) DOI
Understanding the effect of mechanical forces on ovarian cancer progression (2021) DOI